Search clinical trials for: SNDX-5613

Total 498 results

Syndax Pharmaceuticals

Available

Expanded Access Program for SNDX-5613

Relapsed/Refractory Acute Leukemia

United States
M.D. Anderson Cancer Center
Syndax Pharmaceuticals

Not yet recruiting

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Leukemia | HOX Gene

United States
Syndax Pharmaceuticals

Recruiting

Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors

Colorectal Cancer | Solid Tumors

United States
Syndax Pharmaceuticals

Recruiting

Study of Radiolabeled SNDX-5613 in Adults With Acute Leukemia

Acute Leukemia

United States
Uma Borate

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
M.D. Anderson Cancer Center
AbbVie; Syndax Pharmaceuticals; Break Through Cancer

Not yet recruiting

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Acute Myeloid Leukemia

United States
Syndax Pharmaceuticals

Recruiting

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Acute Myeloid Leukemias

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Syndax Pharmaceuticals

Recruiting

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Acute Myeloid Leukemia

United States
Syndax Pharmaceuticals
DevPro Biopharma

Recruiting

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Australia
Syndax Pharmaceuticals

Terminated

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

COVID | ARDS | Coronavirus | Cytokine Storm | Cytokine Release Syndrome

United States
Syndax Pharmaceuticals

Active, not recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201)

Chronic Graft-versus-host-disease

Korea, Republic of, United States, Spain, Taiwan, France, Singapore, Belgium, Germany, Italy, Canada, Israel, Australia, United Kingdom, Greece, Poland, Portugal
Syndax Pharmaceuticals

Active, not recruiting

A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD

Chronic Graft-versus-host-disease

United States
Syndax Pharmaceuticals

Recruiting

A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia

United States, Israel, Spain, Australia, Netherlands, Germany, Canada, France, Italy, Lithuania
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
National Cancer Institute (NCI)

Withdrawn

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Refractory T-Cell Non-Hodgkin Lymphoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC... and other conditions
National Cancer Institute (NCI)

Completed

MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Esanex Inc.

Terminated

Study of SNX-5422 in TP53 Null Cancers

Cancer

United States
National Cancer Institute (NCI)

Completed

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

Neoplasms | Lymphoma

United States
Esanex Inc.
Serenex, Inc.

Completed

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Hematologic Neoplasms

United States
Loci Orthopaedics
North American Science Associates Ltd.

Active, not recruiting

Thumb Hemi-Arthroplasty With Natural Kinematics (THANKS) Trial (THANKS)

Osteoarthritis Thumb Base Joint

Belgium
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5213 10mg in Healthy Subjects

Healthy

Korea, Republic of
Syndax Pharmaceuticals

Completed

A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors

Solid Tumor | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | Metastatic Tumor

United States
National Cancer Institute (NCI)

Completed

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Brain Stem Neoplasm | Pineal Region Neoplasm | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
Esanex Inc.

Completed

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Cancer

United States
Esanex Inc.

Completed

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies

Cancer
Esanex Inc.
Pfizer; Serenex, Inc.

Completed

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; Syndax Pharmaceuticals

Completed

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

United States
Memorial Sloan Kettering Cancer Center
SynDevRx, Inc.

Recruiting

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Breast Cancer | Metastatic Triple-Negative Breast Cancer

United States
Zevra Therapeutics
Rho, Inc.

Active, not recruiting

Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Idiopathic Hypersomnia

United States
Targacept Inc.

Completed

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Syndax Pharmaceuticals

Terminated

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

United States
Syndax Pharmaceuticals

Terminated

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma (ENGAGE-501)

Hodgkin's Lymphoma

United States
University of Pittsburgh

Completed

Reducing Depressive Symptoms in Physically Ill Youth

Depression | Inflammatory Bowel Disease

United States
Esanex Inc.

Terminated

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Cancer

United States
Esanex Inc.
National Cancer Institute (NCI)

Completed

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Lymphoma | Leukemia | Solid Tumor Malignancy | Lymphoid Malignancy (Lymphoma and CLL)

United States
Targacept Inc.

Completed

Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
NexEos Diagnostics, Inc.

Recruiting

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
National Cancer Institute (NCI)

Completed

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Antonio Fojo

Terminated

Entinostat Neuroendocrine (NE) Tumor

Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Completed

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Untreated Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia

United States
Targacept Inc.

Completed

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

Schizophrenia | Cognitive Dysfunction | Negative Symptoms

United States, Serbia, Ukraine, Russian Federation, Hungary, Romania
Targacept Inc.

Completed

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

Schizophrenia | Cognitive Dysfunction

United States, India
Targacept Inc.

Completed

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
National Cancer Institute (NCI)

Completed

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia... and other conditions

United States
National Cancer Institute (NCI)

Completed

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States

Search clinical trials for: SNDX-5613

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations